Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

AI Rating

Rating methodology
Latest close (chg%)245.30-0.59%
Buy price
242.00
Target price260.00
Sell price235.00
P/E TTM22.18
P/E20.43
Confidence70%
Risk score50/100
AI Summary
Bullish technical structure with hierarchical moving average alignment, strong fundamental catalysts including FDA Fast Track for nipocalimab and Spravato blockbuster sales, potential $20B+ divestiture opportunity. Conservative risks mitigated through scaled entry strategy and tighter stop-loss.

Alpha Score

0-10
  • Trend（Score 5/10）

    Johnson & Johnson exhibits a technically sound bullish structure but shows signs of near-term consolidation with momentum indicators suggesting limited upside without significant catalysts.

  • Valuation（Score 4/10）

    Current valuation appears fairly valued to slightly overvalued relative to historical multiples, with moderate P/E ratios and elevated P/B due to intangible assets. Forward P/E of 20.43 suggests moderate premium for quality with 4-6% upside potential.

  • Financial strength（Score 5/10）
    Johnson & Johnson exhibits moderate financial health with adequate liquidity but significant leverage metrics. Current ratio of 1.26 and quick ratio of 1.03 indicate adequate short-term liquidity, while debt-to-equity ratio of 59.67% suggests significant leverage common for large pharmaceutical companies.
  • Profitability（Score 7/10）
    JNJ demonstrates robust profitability with exceptional recent performance including 66.40% gross margin and 50.24% net margin in Q1 2025, though this quarter appears anomalous due to one-time benefits. The company maintains consistent revenue growth and efficient capital utilization.
  • Sentiment（Score 8/10）
    Johnson & Johnson maintains a bullish outlook with strong pipeline progress and dividend appeal, though legal risks require monitoring.
Latest price
$245.30-0.59%
Market cap591.53B
P/E TTM22.18
P/E20.43
Volume5.45M
Turnover1.34B